3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Completed
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
CNS
2
Conditions
Glioblastoma
5
Glioma
3
Brain Neoplasms
3
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Gliosarcoma
2
Sarcoma
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Disease
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Carcinoma
1
Breast Neoplasms
1
Astrocytoma
1
Interventions
XENP 1595
2
Oncolytic Virotherapy
2
Cancer Vaccines
2
Adjuvants, Immunologic
2
pembrolizumab
1
pamiparib
1
interferon gamma-1b
1
glutathione pegylated liposomal doxorubicin
1
Trastuzumab
1
Radiation
1
Interferon-gamma
1
Immunotherapy
1
Cognitive Behavioral Therapy
1
Clinical Laboratory Techniques
1
Antibodies, Monoclonal
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Nervous System Diseases
×
Oncolytic Virotherapy
×
CNS
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled
NCT02197169
2018-07-16
TARGET-I
DNAtrix, Inc.
Phase 1
Completed
37 enrolled